JPWO2014050717A1 - Skin condition improver - Google Patents

Abstract

The present invention effectively ameliorates the deterioration of skin conditions such as sagging, texture, firmness, or frying lines that occur with age. For this purpose, at least one selected from 1) a collagen peptide and 2) proteoglycan, 3) a blood circulation promoting substance, 4) an antioxidant substance, and 5) an estrogen-like substance is used.

Description

  The present invention relates to an agent for improving skin conditions such as sagging, texture, firmness, and spine lines.

  It is known that skin ages with age. As a result, the texture of the skin becomes rough, lack of firmness, sagging occurs, the face line changes due to it, and the frying lines become conspicuous. In particular, it is known that when menopause is reached, the amount of female hormones and substrate components that support the structure of the skin decrease as the amount of female hormone rapidly decreases, and these aging phenomena are strongly recognized.

  As means for solving such problems, foods containing collagen are frequently used. In addition, collagen has a problem of low digestibility, but in recent years, foods containing collagen peptides obtained by hydrolyzing collagen have been utilized (Patent Document 1).

JP-A-9-67262

  An object of the present invention is to provide a composition in an easy-to-ingest form that can effectively improve the deterioration of the skin condition such as sagging, texture, firmness, or splinter that occurs with age. To do.

  The present inventor has found that the skin condition can be effectively improved by combining specific substances.

The present invention relates to, but is not limited to:
[1]
An agent for improving skin condition, comprising at least one of the following substances together with 1) a collagen peptide, and 2) proteoglycan:
3) Blood circulation promoting substance,
4) antioxidants,
5) Estrogen-like substance.
[2]
The skin condition improving agent according to [1], comprising all of the substances 1) to 5).
[3]
[3] The skin condition improving agent according to [1] or [2], wherein the blood circulation promoting substance of 3) is a hihatsu extract.
[4]
[4] The skin condition improving agent according to any one of [1] to [3], wherein the antioxidant of 4) is vitamin C or a salt thereof, or a vitamin C derivative.
[5]
The agent for improving skin condition according to any one of [1] to [4], wherein the estrogenic substance of 5) is flax lignan.
[6] The skin condition improving agent according to any one of [1] to [5], wherein the collagen peptide of 1) has an average molecular weight of 300 to 10,000.
[7]
The skin condition improving agent according to any one of [1] to [6], which is an oral composition.
[8]
The skin condition improving agent according to any one of [1] to [7], which is a food or drink.
[9]
The skin condition improving agent according to [8], which is a beverage.
[10]
The skin condition according to any one of [1] to [9], wherein the improvement of the skin condition is an improvement of one or more skin conditions selected from sagging, texture, firmness, and a constriction line Improver.
[11]
The agent for improving the skin condition according to [9] or [10], wherein the improvement of the skin condition is an improvement of sagging.
[12]
The skin condition improving agent according to any one of [1] to [11], wherein the skin condition to be improved is deteriorated by aging.
[13]
Along with 1) collagen peptide, and 2) proteoglycan, at least one of the following substances:
3) Blood circulation promoting substance,
4) antioxidants,
5) Use of a composition containing an estrogen-like substance in the production of an agent for improving the skin condition.
[14]
A method for improving the condition of the skin, for subjects who need it
Along with 1) collagen peptide, and 2) proteoglycan, at least one of the following substances:
3) Blood circulation promoting substance,
4) antioxidants,
5) A method comprising administering a composition comprising an estrogen-like substance.

  The skin condition-improving agent of the present invention can effectively improve the skin condition such as sagging, texture, firmness, or spine. As a result of improving skin sagging, it is expected that the face line can also be improved.

  The skin condition improving agent of the present invention contains at least one selected from 1) collagen peptides and 2) proteoglycans, 3) blood circulation promoting substances, 4) antioxidant substances, and 5) estrogenic substances.

(Collagen peptide)
The collagen peptide used in the skin condition improving agent of the present invention can be obtained by hydrolyzing denatured collagen such as collagen or gelatin with an enzyme, acid, alkali or the like, but its origin and production method are not limited at all. Not.

  For example, collagen or gelatin as a raw material may be derived from cows, pigs, chickens, fish, etc., and one or more of these can be used as raw materials.

  The enzyme used for collagen peptide preparation may be any enzyme capable of cleaving the peptide bond of collagen or gelatin, for example, collagenase, papain, bromelain, actinidine, ficin, cathepsin, pepsin, chymosin, trypsin, and these Examples thereof include enzyme preparations mixed with enzymes.

  As the acid, for example, hydrochloric acid, sulfuric acid, nitric acid and the like can be used. Examples of the alkali that can be used include sodium hydroxide and calcium hydroxide.

  In the present invention, an aqueous solution of hydrolyzed collagen peptide may be used as it is, or a powdered powder by drying or the like may be used. Moreover, you may use what gave the refinement | purification process normally used to the said aqueous solution as forms, such as aqueous solution and powder. Even when any of these forms is used, the effect of the present invention is not affected.

  The average molecular weight of the collagen peptide is not particularly limited. However, the higher the average molecular weight, the lower the absorbability of the collagen peptide in the body, and the easier it is to solidify at low temperatures. Considering these points, the average molecular weight of the collagen peptide used in the present invention is preferably 300 to 10,000, more preferably 500 to 9,000, and particularly preferably 500 to 6,000. The average molecular weight of the collagen peptide in this specification means a weight average molecular weight, and means a value measured by the Pagii method (gel filtration chromatography method).

  As the collagen peptide, a commercially available product may be used, and a collagen peptide having a preferable molecular weight can be used. For example, the commercially available “Nippi Peptide PRA” (Nippi Co., Ltd.), “Water-soluble collagen peptide SS” (Kyowa Hakko Bio Co., Ltd.), “Collagen Peptide SCP” (Nitta Gelatin Co., Ltd.), “HACP” (Zelice Co., Ltd.) Etc. can be used.

  In the present invention, one type of collagen peptide may be used alone, or two or more types of collagen peptides may be used in combination. The total content of the collagen peptide in the skin condition improving agent of the present invention may vary depending on the use of the improving agent containing it, but is typically 1.0 to 35 w / v%, preferably 2 0.0 to 20 w / v%.

(Proteoglycan)
Proteoglycan is a general term for compounds in which glycosaminoglycans (mucopolysaccharides) such as chondroitin sulfate and dermatan sulfate are covalently bound to a protein as a core. This is a substance that exists in connective tissues such as cartilage and skin of animals and is necessary for maintaining the structure of these tissues. Proteoglycans include, for example, Aggrecan, Versican, Neurocan, Brevican, Decorin, Biglycan, Testican, Perlecan, Distroglycan ( And Dystroglycan), Agrin, and Clostrin.

  The proteoglycan used in the present invention is not limited to its type, origin and production method. For example, any of the above proteoglycans may be used alone, or two or more of them may be used in combination. Among these, aggrecan is preferable, and it can be used alone or in combination with other proteoglycans. In addition, animals derived from proteoglycans are not limited, for example, those derived from animals such as mammals (cow, pigs, etc.), birds (chicken, etc.), fishes (shark, salmon, etc.), molluscs (squid, octopus, etc.) In addition, those derived from one or more animals can be used. Among these, those derived from salmon, particularly those derived from salmon nasal cartilage are preferred, and these can be used alone or in combination with other proteoglycans. The production method may be any known method such as an extraction method using a solvent such as water, an acid (such as acetic acid), an alkali (such as sodium hydroxide or potassium hydroxide), or an alcohol. Although purification is not essential, a known method such as desalting or molecular weight fractionation may be used for purification. The molecular weight of proteoglycan is usually tens of thousands to tens of millions. The molecular weight of the proteoglycan used in the present invention is not particularly limited, but is preferably 100,000 to 2,000,000.

  The total content of proteoglycan in the skin condition improving agent of the present invention may vary depending on the use of the improving agent containing it, but is typically 0.001 to 0.05 w / v%, preferably 0.002 to 0.02 w / v%.

  As a method for measuring the content, any known method may be used. For example, a gel chromatography molecular weight fractionation method can be used. That is, molecular weight fractionation is performed using gel chromatography, and quantification is performed using a proteoglycan standard reagent (proteoglycan, derived from salmon nasal cartilage (Wako Pure Chemical Industries)), or the molecular weight is 10,000 or more and the presence of acidic sugars and proteins Measure the dry matter of the fractions that have been confirmed. The presence of acidic sugar can be confirmed by the carbazole sulfate method, and the presence of protein can be confirmed by absorbance measurement at around 280 nm.

(Blood circulation promoting substance)
As used herein, the term “blood circulation promoting substance” refers to a substance that can promote blood flow in the body through expansion of peripheral blood vessels, suppression of platelet aggregation ability, maintenance of vascular endothelial function, and the like. Blood circulation promoting substances are well known, and any of them may be used in the present invention, but examples include hihatsu extract, ginger extract, pine bark extract, hesperidin, and black pepper extract. Among them, the hihatsu extract is preferable.

  Hihatsu extract can be obtained by concentrating the juice or extract obtained from the ears of Hihatsu (Piper longum) by a method such as pressing or solvent extraction. For extraction, a solvent such as water, methanol, ethanol, or isopropanol can be used. Further, although not essential, purification may be performed.

  In the present invention, one kind of blood circulation promoting substance may be used alone, or two or more kinds of blood circulation promoting substances may be used in combination.

  The total content of the blood circulation promoting substance in the skin condition improving agent of the present invention may vary depending on the use of the improving agent containing it, but is typically 0.003 to 3 w / v%, preferably 0.1-1 w / v%.

(Antioxidant)
As used herein, the term “antioxidant” refers to a substance that can suppress an oxidation reaction in a living body. Antioxidants are well known and any of them may be used in the present invention. Examples include vitamin E, vitamin A, carotenoids, vitamin B, flavonoids, polyphenols, glutathione, oligomeric pro Examples include anthocyanidins, vitamin K, β-carotene, astaxanthin, vitamin C (ascorbic acid) or salts thereof, and vitamin C derivatives. Among these, vitamin C or a salt thereof, or a vitamin C acid derivative is preferable, and vitamin C or a salt thereof is more preferable. Vitamin C derivatives are known and include all compounds that release vitamin C in vivo or in vitro and their solvates, hydrates and salts. Any vitamin C derivative may be used in the present invention, and examples include ascorbic acid glucoside, ascorbic acid phosphate, and salts and hydrates thereof.

  Vitamin C or a salt thereof can also be blended in the form of a cherry blossom extract or a lotus cup extract containing it. The cherry blossom extract and the lotus cup extract are obtained by concentrating the juice and extract obtained from the cherry blossom and the fruit of the honeysuckle lotus cup (Lonicera caerulea L. ssp. Edulis Hulten) by methods such as pressing and solvent extraction, respectively. Can be obtained. For extraction, a solvent such as water, methanol, ethanol, or isopropanol can be used. Further, although not essential, purification may be performed.

  In the present invention, one kind of antioxidant substance may be used alone, or two or more kinds of antioxidant substances may be used in combination.

  The total content of antioxidants in the skin condition improving agent of the present invention may vary depending on the use of the improving agent containing it, but is typically 0.01-2 w / v%, preferably 0.05-1 w / v%.

(Estrogen-like substance)
As used herein, the term “estrogen-like substance” refers to a substance having a physiological action similar to that of the female hormone estrogen. Estrogen-like substances are well known, and any of them may be used in the present invention. Examples thereof include flax lignan, soybean isoflavone, isoxanthohumol, and 8-prenylnaringenin. Among these, flax lignan is preferable.

  Flax lignan is a series of lignan compounds, such as secoisolariciresinol diglycoside (SDG), its metabolites enterodiol and enterolactone, matayresinol, pinoresinol, isolariciresinol, contained in flax seeds It is. Flax lignan is contained in the flaxseed extract, and the extract may be blended with the skin condition improving agent of the present invention. The flaxseed extract can be obtained by concentrating the juice or extract obtained from flaxseed or flaxseed meal by a method such as pressing or solvent extraction. For extraction, a solvent such as water, methanol, ethanol, or isopropanol can be used. Further, although not essential, purification may be performed.

  In the present invention, one kind of estrogen-like substance may be used alone, or two or more kinds of estrogen-like substances may be used in combination.

  The total content of the estrogen-like substance in the skin condition-improving agent of the present invention may vary depending on the use of the improving agent containing it. It is 0001 to 0.2 w / v%, preferably 0.001 to 0.1 w / v%.

(Other ingredients)
The skin condition improving agent of the present invention may further contain an additional component as long as the effect of the present invention is not adversely affected. Such components are, for example, antioxidants, pigments, preservatives, seasonings, sweeteners, acidulants, pH adjusters, stabilizers, emulsifiers, nutrient enhancers, fragrances, fruit juices. In the skin condition improving agent of the present invention, each active ingredient can be used in combination with ingredients such as ceramide, hyaluronic acid, placenta, and CoQ10.

(Dosage form)
The skin condition improving agent of the present invention is preferably an oral composition, and its form is not particularly limited. For example, it can be provided in the form of tablets, granules, liquids, capsules, pills, powders, troches, gel foods, and cereals. These can be provided as food and drink. In particular, beverages are preferred. Alternatively, it may be a pharmaceutical composition.

  The agent for improving the skin condition of the present invention can be packed in a container. The form of the container is not limited at all, and examples include a bottle, a can, a plastic bottle, a paper pack, an aluminum pouch, a vinyl pouch, or a blow molded container.

  Examples of preferred combinations in the present invention are 1) collagen peptide, 2) proteoglycan, 3) baboon extract, 4) vitamin C or a salt thereof, or vitamin C derivative, and 5) flax lignan, and component 4) is preferably Vitamin C or its salt.

  In another aspect, the present invention provides a composition comprising at least one selected from 1) a collagen peptide and 2) proteoglycan, 3) a blood circulation promoting substance, 4) an antioxidant, and 5) an estrogen-like substance. It is used in the manufacture of a skin condition improving agent. In another aspect, the present invention is a method for improving skin condition, which is used in combination with 1) a collagen peptide and 2) a proteoglycan, 3) a blood circulation promoting substance, 4) Administering a composition comprising an antioxidant and 5) at least one selected from estrogenic substances. Administration subjects include mammals such as humans. Specific selection, blending amount, intake amount, and the like of each component in the use and method can be determined as appropriate based on the above description regarding the skin condition improving agent.

  For the sake of clarity, the numerical range represented by the upper limit value and the lower limit value in the present specification, that is, “lower limit value to upper limit value” includes the lower limit value and the upper limit value. For example, the range represented by “1-2” includes 1 and 2.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated, this invention is not limited to these.

  Beverages used for the test were prepared as follows.

  Collagen nasal cartilage extract containing 20% collagen peptide (molecular weight 3,000), baboon extract, ascorbic acid, proteoglycan (molecular weight about 450,000), flaxseed extract containing 40% SDG, other sweeteners, acidulants, flavorings A sample A (beverage 50 ml) containing the components shown in Table 1 was produced by adding an appropriate amount of the mixture and mixing according to a conventional method.

  The following tests were performed using the sample A manufactured in Example 1.

  Twenty-two women in their 40s and 60s were selected as subjects. The average age of the subjects was 54.2 ± 6.5 years. The test was an open test. The subject took sample A once a day for 8 weeks, and the skin was inspected before ingestion, at 2 weeks, 4 weeks, and 8 weeks before ingestion. Specifically, skin elasticity measurement, skin texture image analysis, and visual judgment by a beauty specialist were performed.

  For skin elasticity, the return rate of the right cheek was measured using a cut meter MPA580 manufactured by Integral. This is related to skin firmness. For texture image analysis, a replica of the right cheek was collected and the number of textures was measured using a texture analysis device ASA-03RXD manufactured by Asahi Biomed. In the visual evaluation, a judge specialized in beauty performed a visual inspection of the sagittal line and sagging of the cheeks, and the determination result was evaluated based on a five-level score.

  Table 2 shows changes in skin elasticity. Taking Sample A for 8 weeks increased the average return rate from 64.3 ± 2.9% to 69.5 ± 4.1%.

  Table 3 shows the results of the texture image analysis. By ingesting sample A for 8 weeks, the number of textures increased from 1.34 ± 0.45 / mm to 1.57 ± 0.46 / mm, resulting in fine texture.

  Table 4 shows the results of visual evaluation. Table 5 shows the evaluation criteria related to the visual evaluation. By taking Sample A for 8 weeks, the scoring score value of 2.14 ± 0.77 to 2.73 ± 0.70 and the sagging sagging score value of 2.95 ± 0.84 to 3. Improved to 59 ± 0.67.

  As described above, the skin condition improving agent of the present invention exhibited an excellent improvement effect on the skin condition.

Claims (14)

An agent for improving skin condition, comprising at least one of the following substances together with 1) a collagen peptide, and 2) proteoglycan:
3) Blood circulation promoting substance,
4) antioxidants,
5) Estrogen-like substance.   The skin condition improving agent according to claim 1, comprising all of the substances 1) to 5).   The agent for improving the skin condition according to claim 1 or 2, wherein the blood circulation promoting substance of 3) is a chickpea extract.   The agent for improving skin condition according to any one of claims 1 to 3, wherein the antioxidant of 4) is vitamin C or a salt thereof, or a vitamin C derivative.   The skin condition improving agent according to any one of claims 1 to 4, wherein the estrogenic substance of 5) is flax lignan.   The skin condition improving agent according to any one of claims 1 to 5, wherein the collagen peptide of 1) has an average molecular weight of 300 to 10,000.   The skin condition improving agent according to any one of claims 1 to 6, which is an oral composition.   The skin condition improver according to any one of claims 1 to 7, which is a food or drink.   The skin condition improving agent according to claim 8, which is a beverage.   The improvement of the skin condition according to any one of claims 1 to 9, wherein the improvement of the skin condition is an improvement of one or more skin conditions selected from sagging, texture, firmness, and a constriction line. Agent.   The skin condition improving agent according to claim 9 or 10, wherein the improvement of the skin condition is an improvement of sagging.   The skin condition improving agent according to any one of claims 1 to 11, wherein the skin condition to be improved is deteriorated by aging. Along with 1) collagen peptide, and 2) proteoglycan, at least one of the following substances:
3) Blood circulation promoting substance,
4) antioxidants,
5) Use of a composition containing an estrogen-like substance in the production of an agent for improving the skin condition. A method for improving the condition of the skin, for subjects who need it
Along with 1) collagen peptide, and 2) proteoglycan, at least one of the following substances:
3) Blood circulation promoting substance,
4) antioxidants,
5) A method comprising administering a composition comprising an estrogen-like substance.